Logo image of ENTA

ENANTA PHARMACEUTICALS INC (ENTA) Stock Fundamental Analysis

NASDAQ:ENTA - Nasdaq - US29251M1062 - Common Stock - Currency: USD

8.1  -0.2 (-2.41%)

Fundamental Rating

2

Overall ENTA gets a fundamental rating of 2 out of 10. We evaluated ENTA against 571 industry peers in the Biotechnology industry. Both the profitability and financial health of ENTA have multiple concerns. ENTA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ENTA had negative earnings in the past year.
ENTA had a negative operating cash flow in the past year.
ENTA had negative earnings in each of the past 5 years.
ENTA had negative operating cash flow in 4 of the past 5 years.
ENTA Yearly Net Income VS EBIT VS OCF VS FCFENTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

The Return On Assets of ENTA (-30.10%) is better than 67.85% of its industry peers.
Looking at the Return On Equity, with a value of -93.84%, ENTA is in line with its industry, outperforming 47.25% of the companies in the same industry.
Industry RankSector Rank
ROA -30.1%
ROE -93.84%
ROIC N/A
ROA(3y)-30.73%
ROA(5y)-23.53%
ROE(3y)-63.25%
ROE(5y)-43.49%
ROIC(3y)N/A
ROIC(5y)N/A
ENTA Yearly ROA, ROE, ROICENTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60 -80

1.3 Margins

ENTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENTA Yearly Profit, Operating, Gross MarginsENTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

ENTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ENTA has been increased compared to 1 year ago.
The number of shares outstanding for ENTA has been increased compared to 5 years ago.
ENTA has a worse debt/assets ratio than last year.
ENTA Yearly Shares OutstandingENTA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ENTA Yearly Total Debt VS Total AssetsENTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -1.04, we must say that ENTA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.04, ENTA is in line with its industry, outperforming 57.90% of the companies in the same industry.
ENTA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.01, ENTA perfoms like the industry average, outperforming 41.74% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -1.04
ROIC/WACCN/A
WACC14.73%
ENTA Yearly LT Debt VS Equity VS FCFENTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 5.47 indicates that ENTA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.47, ENTA is in line with its industry, outperforming 57.73% of the companies in the same industry.
ENTA has a Quick Ratio of 5.47. This indicates that ENTA is financially healthy and has no problem in meeting its short term obligations.
ENTA's Quick ratio of 5.47 is in line compared to the rest of the industry. ENTA outperforms 58.26% of its industry peers.
Industry RankSector Rank
Current Ratio 5.47
Quick Ratio 5.47
ENTA Yearly Current Assets VS Current LiabilitesENTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

2

3. Growth

3.1 Past

ENTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.54%, which is quite impressive.
ENTA shows a decrease in Revenue. In the last year, the revenue decreased by -9.55%.
ENTA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -19.91% yearly.
EPS 1Y (TTM)24.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.54%
Revenue 1Y (TTM)-9.55%
Revenue growth 3Y-11.36%
Revenue growth 5Y-19.91%
Sales Q2Q%-5.8%

3.2 Future

ENTA is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -8.50% yearly.
The Revenue is expected to grow by 1.89% on average over the next years.
EPS Next Y20.77%
EPS Next 2Y6.75%
EPS Next 3Y5.61%
EPS Next 5Y-8.5%
Revenue Next Year-11.91%
Revenue Next 2Y-15.23%
Revenue Next 3Y-19.29%
Revenue Next 5Y1.89%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ENTA Yearly Revenue VS EstimatesENTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M 250M
ENTA Yearly EPS VS EstimatesENTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ENTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ENTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENTA Price Earnings VS Forward Price EarningsENTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENTA Per share dataENTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.75%
EPS Next 3Y5.61%

More info and screens

0

5. Dividend

5.1 Amount

ENTA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENANTA PHARMACEUTICALS INC

NASDAQ:ENTA (2/20/2025, 2:32:38 PM)

8.1

-0.2 (-2.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-10 2025-02-10/amc
Earnings (Next)05-05 2025-05-05/amc
Inst Owners104.73%
Inst Owner Change-9.31%
Ins Owners6.21%
Ins Owner Change2.61%
Market Cap172.77M
Analysts75.71
Price Target18.16 (124.2%)
Short Float %16.87%
Short Ratio5.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.48%
Min EPS beat(2)-14.94%
Max EPS beat(2)23.9%
EPS beat(4)2
Avg EPS beat(4)6.4%
Min EPS beat(4)-14.94%
Max EPS beat(4)27.64%
EPS beat(8)5
Avg EPS beat(8)8.56%
EPS beat(12)7
Avg EPS beat(12)5.89%
EPS beat(16)9
Avg EPS beat(16)2.41%
Revenue beat(2)0
Avg Revenue beat(2)-11.88%
Min Revenue beat(2)-20.14%
Max Revenue beat(2)-3.61%
Revenue beat(4)2
Avg Revenue beat(4)-4.33%
Min Revenue beat(4)-20.14%
Max Revenue beat(4)3.89%
Revenue beat(8)4
Avg Revenue beat(8)-4.35%
Revenue beat(12)5
Avg Revenue beat(12)-5.34%
Revenue beat(16)5
Avg Revenue beat(16)-6.21%
PT rev (1m)-6.67%
PT rev (3m)-25%
EPS NQ rev (1m)-6.7%
EPS NQ rev (3m)-6.1%
EPS NY rev (1m)8.45%
EPS NY rev (3m)11.72%
Revenue NQ rev (1m)-4.17%
Revenue NQ rev (3m)-8.73%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.59
P/FCF N/A
P/OCF N/A
P/B 1.55
P/tB 1.55
EV/EBITDA N/A
EPS(TTM)-4.95
EYN/A
EPS(NY)-4.71
Fwd EYN/A
FCF(TTM)-4.52
FCFYN/A
OCF(TTM)-3.31
OCFYN/A
SpS3.12
BVpS5.24
TBVpS5.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.1%
ROE -93.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.73%
ROA(5y)-23.53%
ROE(3y)-63.25%
ROE(5y)-43.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1002.94%
Cap/Sales 38.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.47
Quick Ratio 5.47
Altman-Z -1.04
F-Score4
WACC14.73%
ROIC/WACCN/A
Cap/Depr(3y)407.44%
Cap/Depr(5y)256.94%
Cap/Sales(3y)13.48%
Cap/Sales(5y)8.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.54%
EPS Next Y20.77%
EPS Next 2Y6.75%
EPS Next 3Y5.61%
EPS Next 5Y-8.5%
Revenue 1Y (TTM)-9.55%
Revenue growth 3Y-11.36%
Revenue growth 5Y-19.91%
Sales Q2Q%-5.8%
Revenue Next Year-11.91%
Revenue Next 2Y-15.23%
Revenue Next 3Y-19.29%
Revenue Next 5Y1.89%
EBIT growth 1Y22.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.38%
EBIT Next 3Y-13.82%
EBIT Next 5YN/A
FCF growth 1Y13.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.13%
OCF growth 3YN/A
OCF growth 5YN/A